Dobesilic Acid

Dobesilic Acid

SCHEMBL78224

O=S(=O)(O)c1cc(O)ccc1O.[K]

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.70
HSD17B10 Q99714 3/20 0.70
HPGD P15428 1/20 0.70
HIF1A Q16665 1/20 0.70
PTGS1 P23219 1/20 0.61
EGFR P00533 1/20 0.56
GAA P10253 3/20 0.55
POLB P06746 2/20 0.55
GFER P55789 1/20 0.55
ALPL P05186 1/20 0.53
ALPI P09923 1/20 0.53
ALPG P10696 1/20 0.53
DNMT1 P26358 1/20 0.53
MCL1 Q07820 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ALDH1A1 P00352 3/20 0.49
PKM P14618 1/20 0.49
MPL P40238 2/20 0.43
NSD2 O96028 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dobesilic Acid SCHEMBL232087 0.98 LMNA (0.72) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL29389625 0.98 LMNA (0.72) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL344443 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL214799 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL9790423 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL15364076 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL370202 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL78222 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL866670 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL10589964 0.95 HSD17B10 (0.70) LMNAHSD17B10HPGDHIF1APTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4663823-A1 METHOD FOR PREPARING POLYESTER FIBER UNEASY TO PRODUCE MICROPLASTICS DURING USE Jiangsu Hengli Chemical Fibre Co., Ltd. (CN) 2025-12-17 EP claimed
CN-119008080-A Preparation method and application of conductive paste for carbon-coated aluminum foil 广东莱尔新材料科技股份有限公司 2024-11-22 CN claimed
WO-2024164573-A1 METHOD FOR PREPARING POLYESTER FIBER UNEASY TO PRODUCE MICROPLASTICS DURING USE 江苏恒力化纤股份有限公司 2024-08-15 WO claimed
WO-2024164576-A1 PREPARATION METHOD FOR HIGH-STRENGTH BIODEGRADABLE POLYESTER FIBER 江苏恒力化纤股份有限公司 2024-08-15 WO claimed
WO-2024164578-A1 PREPARATION OF IONIC COPOLYMERIZED FLAME-RETARDANT POLYESTER MASTERBATCH AND USE IN FIBERS 江苏恒力化纤股份有限公司 2024-08-15 WO claimed
WO-2024164575-A1 IONIC POLYESTER MASTERBATCH CARRIER AND PREPARATION METHOD THEREFOR 江苏恒力化纤股份有限公司 2024-08-15 WO claimed
CN-118213584-A Sodium lignin sulfonate doped sulfonated polyarylether nitrile proton exchange membrane and preparation method thereof 成都欧赛医疗器械有限公司 2024-06-18 CN claimed
CN-117384463-B Carbon fiber reinforced sulfonated PEEK composite material and preparation method thereof 季华实验室 2024-03-08 CN claimed
CN-117089096-B Preparation method of flame-retardant anti-dripping polyester film 江苏恒力化纤股份有限公司 2024-02-06 CN claimed
CN-117384463-A Carbon fiber reinforced sulfonated PEEK composite material and preparation method thereof 季华实验室 2024-01-12 CN claimed
WO-2008020037-A1 USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING OBESITY, HIRSUTISM, HYPERTRICOSIS AND VIRAL WARTS ACTION MEDICINES, S.L. (ES) 2008-02-21 WO claimed
WO-2008020034-A1 USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF HEMANGIOMAS OR HEMANGIOBLASTOMAS ACTION MEDICINES, S.L. (ES) 2008-02-21 WO claimed
WO-2008020042-A1 USE OF 2, 5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTIVE DISEASES ACTION MEDICINES, S.L. (ES) 2008-02-21 WO claimed
WO-2008020025-A1 USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS ACTION MEDICINES, S.L. (ES) 2008-02-21 WO claimed
US-20070149618-A1 Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis ACTION MEDICINES, S.L. 2007-06-28 US claimed
US-6913694-B2 Selective membrane having a high fouling resistance SAEHAN INDUSTRIES INCORPORATION (KR) 2005-07-05 US claimed
US-20030121844-A1 Selective membrane having a high fouling resistance SAEHAN INDUSTRIES INCORPORATION (KR) 2003-07-03 US claimed
EP-0297916-B1 CONTROL OF CORROSION IN AQUEOUS SYSTEMS W.R. Grace & Co.-Conn. (US) 1992-05-13 EP claimed
US-4847001-A DIHYDROXYBENZENE SULFONIC ACIDS AND SALTS W. R. GRACE & CO.-CONN. (US) 1989-07-11 US claimed
EP-0297916-A1 Control of corrosion in aqueous systems W.R. Grace & Co.-Conn. (US) 1989-01-04 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149618-A1 Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis IL2, IL2RA, IL5 LMNA 4181/4885HSD17B10 1497/4885HPGD 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.